Endocytosis of PEGylated agents enhances cancer imaging and anticancer efficacy

Kuo Hsiang Chuang, Hsin Ell Wang, Fang Ming Chen, Shey Cherng Tzou, Chiu Min Cheng, Ya Chen Chang, Wei Lung Tseng, Jentaie Shiea, Shiu Ru Lin, Jaw Yuan Wang, Bing Mae Chen, Steve R. Roffler, Tian Lu Cheng

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

PEGylated nanoparticles and macromolecules are increasingly used in cancer imaging and anticancer treatment. The role of receptor-mediated endocytosis in the efficacy of these agents, however, has not been clearly defined. Here, we developed a matched pair of endocytic and nonendocytic receptors to directly and unambiguously assess this issue. The ligand-binding domains of the low-density lipoprotein receptor (LDLR) or a truncated LDLR lacking the NPXY endocytosis motif (ΔLDLR) were replaced with an anti-polyethylene glycol antibody (αPEG) to form endocytic αPEG-LDLR and nonendocytic αPEG-ΔLDLR receptors. The receptors were stably expressed at similar levels on the surface of HCC36 cells. HCC36/αPEG-LDLR cells, but not HCC36/αPEG-ΔLDLR cells, rapidly endocytosed PEG-quantum dots and PEG-liposomal doxorubicin (Lipo-Dox) in vitro and in vivo. Lipo-Dox was significantly more cytotoxic to HCC36/αPEG-LDLR cells than to HCC36/αPEG-ΔLDLR cells. HCC36/αPEG-LDLR tumors also accumulated significantly more PEGylated near-IR probes (PEG-NIR797) and PEG-liposomal-111In than HCC36/αPEG-ΔLDLR tumors in vivo. Furthermore, Lipo-Dox more significantly suppressed the growth of established HCC36/αPEG-LDLR tumors as compared with HCC36/αPEG-ΔLDLR tumors. Our data show that endocytosis of PEGylated probes and drugs enhances both cancer imaging and anticancer efficacy, indicating that endocytic receptors are superior targets for the design of cancer imaging probes and immunoliposomal drugs.

Original languageEnglish
Pages (from-to)1903-1912
Number of pages10
JournalMolecular Cancer Therapeutics
Volume9
Issue number6
DOIs
Publication statusPublished - Jun 2010
Externally publishedYes

Fingerprint

Endocytosis
LDL Receptors
Antibodies
Neoplasms
Quantum Dots
Lipoprotein(a)
Pharmaceutical Preparations
Nanoparticles

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chuang, K. H., Wang, H. E., Chen, F. M., Tzou, S. C., Cheng, C. M., Chang, Y. C., ... Cheng, T. L. (2010). Endocytosis of PEGylated agents enhances cancer imaging and anticancer efficacy. Molecular Cancer Therapeutics, 9(6), 1903-1912. https://doi.org/10.1158/1535-7163.MCT-09-0899

Endocytosis of PEGylated agents enhances cancer imaging and anticancer efficacy. / Chuang, Kuo Hsiang; Wang, Hsin Ell; Chen, Fang Ming; Tzou, Shey Cherng; Cheng, Chiu Min; Chang, Ya Chen; Tseng, Wei Lung; Shiea, Jentaie; Lin, Shiu Ru; Wang, Jaw Yuan; Chen, Bing Mae; Roffler, Steve R.; Cheng, Tian Lu.

In: Molecular Cancer Therapeutics, Vol. 9, No. 6, 06.2010, p. 1903-1912.

Research output: Contribution to journalArticle

Chuang, KH, Wang, HE, Chen, FM, Tzou, SC, Cheng, CM, Chang, YC, Tseng, WL, Shiea, J, Lin, SR, Wang, JY, Chen, BM, Roffler, SR & Cheng, TL 2010, 'Endocytosis of PEGylated agents enhances cancer imaging and anticancer efficacy', Molecular Cancer Therapeutics, vol. 9, no. 6, pp. 1903-1912. https://doi.org/10.1158/1535-7163.MCT-09-0899
Chuang, Kuo Hsiang ; Wang, Hsin Ell ; Chen, Fang Ming ; Tzou, Shey Cherng ; Cheng, Chiu Min ; Chang, Ya Chen ; Tseng, Wei Lung ; Shiea, Jentaie ; Lin, Shiu Ru ; Wang, Jaw Yuan ; Chen, Bing Mae ; Roffler, Steve R. ; Cheng, Tian Lu. / Endocytosis of PEGylated agents enhances cancer imaging and anticancer efficacy. In: Molecular Cancer Therapeutics. 2010 ; Vol. 9, No. 6. pp. 1903-1912.
@article{267f1da2323b40489ac999eda0ccd858,
title = "Endocytosis of PEGylated agents enhances cancer imaging and anticancer efficacy",
abstract = "PEGylated nanoparticles and macromolecules are increasingly used in cancer imaging and anticancer treatment. The role of receptor-mediated endocytosis in the efficacy of these agents, however, has not been clearly defined. Here, we developed a matched pair of endocytic and nonendocytic receptors to directly and unambiguously assess this issue. The ligand-binding domains of the low-density lipoprotein receptor (LDLR) or a truncated LDLR lacking the NPXY endocytosis motif (ΔLDLR) were replaced with an anti-polyethylene glycol antibody (αPEG) to form endocytic αPEG-LDLR and nonendocytic αPEG-ΔLDLR receptors. The receptors were stably expressed at similar levels on the surface of HCC36 cells. HCC36/αPEG-LDLR cells, but not HCC36/αPEG-ΔLDLR cells, rapidly endocytosed PEG-quantum dots and PEG-liposomal doxorubicin (Lipo-Dox) in vitro and in vivo. Lipo-Dox was significantly more cytotoxic to HCC36/αPEG-LDLR cells than to HCC36/αPEG-ΔLDLR cells. HCC36/αPEG-LDLR tumors also accumulated significantly more PEGylated near-IR probes (PEG-NIR797) and PEG-liposomal-111In than HCC36/αPEG-ΔLDLR tumors in vivo. Furthermore, Lipo-Dox more significantly suppressed the growth of established HCC36/αPEG-LDLR tumors as compared with HCC36/αPEG-ΔLDLR tumors. Our data show that endocytosis of PEGylated probes and drugs enhances both cancer imaging and anticancer efficacy, indicating that endocytic receptors are superior targets for the design of cancer imaging probes and immunoliposomal drugs.",
author = "Chuang, {Kuo Hsiang} and Wang, {Hsin Ell} and Chen, {Fang Ming} and Tzou, {Shey Cherng} and Cheng, {Chiu Min} and Chang, {Ya Chen} and Tseng, {Wei Lung} and Jentaie Shiea and Lin, {Shiu Ru} and Wang, {Jaw Yuan} and Chen, {Bing Mae} and Roffler, {Steve R.} and Cheng, {Tian Lu}",
year = "2010",
month = "6",
doi = "10.1158/1535-7163.MCT-09-0899",
language = "English",
volume = "9",
pages = "1903--1912",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Endocytosis of PEGylated agents enhances cancer imaging and anticancer efficacy

AU - Chuang, Kuo Hsiang

AU - Wang, Hsin Ell

AU - Chen, Fang Ming

AU - Tzou, Shey Cherng

AU - Cheng, Chiu Min

AU - Chang, Ya Chen

AU - Tseng, Wei Lung

AU - Shiea, Jentaie

AU - Lin, Shiu Ru

AU - Wang, Jaw Yuan

AU - Chen, Bing Mae

AU - Roffler, Steve R.

AU - Cheng, Tian Lu

PY - 2010/6

Y1 - 2010/6

N2 - PEGylated nanoparticles and macromolecules are increasingly used in cancer imaging and anticancer treatment. The role of receptor-mediated endocytosis in the efficacy of these agents, however, has not been clearly defined. Here, we developed a matched pair of endocytic and nonendocytic receptors to directly and unambiguously assess this issue. The ligand-binding domains of the low-density lipoprotein receptor (LDLR) or a truncated LDLR lacking the NPXY endocytosis motif (ΔLDLR) were replaced with an anti-polyethylene glycol antibody (αPEG) to form endocytic αPEG-LDLR and nonendocytic αPEG-ΔLDLR receptors. The receptors were stably expressed at similar levels on the surface of HCC36 cells. HCC36/αPEG-LDLR cells, but not HCC36/αPEG-ΔLDLR cells, rapidly endocytosed PEG-quantum dots and PEG-liposomal doxorubicin (Lipo-Dox) in vitro and in vivo. Lipo-Dox was significantly more cytotoxic to HCC36/αPEG-LDLR cells than to HCC36/αPEG-ΔLDLR cells. HCC36/αPEG-LDLR tumors also accumulated significantly more PEGylated near-IR probes (PEG-NIR797) and PEG-liposomal-111In than HCC36/αPEG-ΔLDLR tumors in vivo. Furthermore, Lipo-Dox more significantly suppressed the growth of established HCC36/αPEG-LDLR tumors as compared with HCC36/αPEG-ΔLDLR tumors. Our data show that endocytosis of PEGylated probes and drugs enhances both cancer imaging and anticancer efficacy, indicating that endocytic receptors are superior targets for the design of cancer imaging probes and immunoliposomal drugs.

AB - PEGylated nanoparticles and macromolecules are increasingly used in cancer imaging and anticancer treatment. The role of receptor-mediated endocytosis in the efficacy of these agents, however, has not been clearly defined. Here, we developed a matched pair of endocytic and nonendocytic receptors to directly and unambiguously assess this issue. The ligand-binding domains of the low-density lipoprotein receptor (LDLR) or a truncated LDLR lacking the NPXY endocytosis motif (ΔLDLR) were replaced with an anti-polyethylene glycol antibody (αPEG) to form endocytic αPEG-LDLR and nonendocytic αPEG-ΔLDLR receptors. The receptors were stably expressed at similar levels on the surface of HCC36 cells. HCC36/αPEG-LDLR cells, but not HCC36/αPEG-ΔLDLR cells, rapidly endocytosed PEG-quantum dots and PEG-liposomal doxorubicin (Lipo-Dox) in vitro and in vivo. Lipo-Dox was significantly more cytotoxic to HCC36/αPEG-LDLR cells than to HCC36/αPEG-ΔLDLR cells. HCC36/αPEG-LDLR tumors also accumulated significantly more PEGylated near-IR probes (PEG-NIR797) and PEG-liposomal-111In than HCC36/αPEG-ΔLDLR tumors in vivo. Furthermore, Lipo-Dox more significantly suppressed the growth of established HCC36/αPEG-LDLR tumors as compared with HCC36/αPEG-ΔLDLR tumors. Our data show that endocytosis of PEGylated probes and drugs enhances both cancer imaging and anticancer efficacy, indicating that endocytic receptors are superior targets for the design of cancer imaging probes and immunoliposomal drugs.

UR - http://www.scopus.com/inward/record.url?scp=77953473337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953473337&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-09-0899

DO - 10.1158/1535-7163.MCT-09-0899

M3 - Article

VL - 9

SP - 1903

EP - 1912

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 6

ER -